Relapsing polychondritis: clinical presentations, disease activity and outcomes
Aman Sharma(Great Ormond Street Hospital), Surjit Singh(Post Graduate Institute of Medical Education and Research), Varun Dhir(Post Graduate Institute of Medical Education and Research), Arjun Law(University of Toronto), Naresh K. Panda(Post Graduate Institute of Medical Education and Research), Rajesh Vijayvergiya(Post Graduate Institute of Medical Education and Research), Vinay Sagar(University of Rome Tor Vergata), Kusum Sharma(Post Graduate Institute of Medical Education and Research), P Bambery(University of Queensland), Ashok Gupta, Ajay Wanchu(Oregon Health & Science University)
Cited by 39
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k